Journal article

Clinical Potential of Histone Deacetylase Inhibitors as Stand Alone Therapeutics and in Combination with Other Chemotherapeutics or Radiotherapy for Cancer

Tom C Karagiannis, Assam El-Osta

Epigenetics | TAYLOR & FRANCIS INC | Published : 2006


Histone deacetylase inhibitors are emerging as a new class of cancer chemotherapeutics and already are being heralded as the first anti-cancer drugs targeting the epigenome. Through histone hyperacetylation-mediated changes in chromatin conformation and gene expression, histone deacetylase inhibitors induce differentiation, cell cycle arrest, apoptosis, growth inhibition and cell death, which are more pronounced in transformed cell-lines than in normal cells. Additional anti-cancer effects of HDAC inhibitors include inhibition of migration, invasion and angiogenesis in vivo. Indeed, clinical anti-cancer activity has been observed using HDAC inhibitors as single agents or in combination with ..

View full abstract

University of Melbourne Researchers


Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

The support of the Australian Institute of Nuclear Science and Engineering is acknowledged. T. C. K. was the recipient of AINSE awards. Molecular Radiation Biology and Epigenetics in Human Health and Disease Laboratories are supported by the National Health and Medical Research Council of Australia (350359 and 268905).